{"filings":[{"id":95436,"accession_number":"0001104659-26-050318","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.01","3.01","3.03","5.01","5.02","5.03","9.01"],"status":"ready","headline":"Arcellx completes acquisition by Gilead Sciences subsidiary for $115 per share plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer expired with 38,795,604 shares tendered, representing ~77.2% of outstanding shares.","Merger consideration: $115 per share cash plus one contingent value right of up to $5 per CVR payable by 2030.","Aggregate funds used by Gilead to consummate the offer and merger were approximately $7.1 billion.","Arcellx requested delisting from Nasdaq and intends to terminate SEC registration.","All directors and officers resigned; new directors and officers appointed from Gilead subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108515,"accession_number":"0001193125-26-063955","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Per-share consideration: $115 cash at closing + one CVR worth up to $5 contingent on anito-cel cumulative sales exceeding $6B by Dec 31, 2029.","Gilead gains full control of anito-cel, a BCMA-directed CAR T-cell therapy currently under FDA review with a PDUFA date of Dec 23, 2026.","Support stockholders (entities affiliated with NEA, SR One, directors, officers) holding ~10.3% of shares have agreed to tender in the offer.","Transaction is structured as a tender offer followed by a Section 251(h) merger; Arcellx may pay a $260M termination fee under specified circumstances.","Arcellx will conduct business in ordinary course and is subject to a no-shop restriction prior to the Offer Acceptance Time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124959,"accession_number":"0001193125-25-311276","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcellx: anito-cel achieves 96% ORR, 74% CR/sCR in pivotal RRMM study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["96% ORR (112/117) and 74% CR/sCR (86/117); 95% MRD negativity (91/96) at 10^-5 sensitivity.","12-month PFS 82.1%, OS 94.0%; 24-month PFS 61.7%, OS 83.0% in 4L+ triple/penta-refractory patients.","No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) observed; all patients dosed >12 months.","Company reiterates planned 2026 commercial launch; building commercial and medical affairs organization.","Data presented at ASH; BLA submission underway with Oct 2025 data cutoff."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124958,"accession_number":"0001193125-25-266866","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcellx Q3 2025 net loss widens to $55.8M; collaboration revenue drops 81%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities of $576.0M as of Sep 30, 2025; expected to fund operations into 2028.","Collaboration revenue fell to $4.9M from $26.0M YoY, driven by completion of anito-cel dosing in iMMagine-1 trial.","R&D expenses decreased to $35.1M from $39.2M YoY; G&A expenses rose to $31.6M from $20.5M YoY on commercial readiness costs.","Net loss was $55.8M compared to $25.9M in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":20632000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141664,"accession_number":"0000950170-25-105015","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcellx reports 97% ORR from anito-cel Phase 2; FDA clears ACLX-004 IND; Q2 net loss $52.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 iMMagine-1: 97% ORR, 68% CR/sCR at 12.6 months; no delayed neurotoxicity events observed.","FDA cleared IND for ACLX-004 (CD33/CD123) ARC-SparX platform for AML.","Q2 2025 net loss $52.8M vs $27.2M in Q2 2024; rev $7.6M (down from $27.4M).","Cash $537.6M expected to fund operations into 2028.","Plan to launch anito-cel at >160 US treatment centers within first year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159558,"accession_number":"0001193125-25-129522","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcellx shareholders elect three Class III directors, approve say-on-pay, and ratify PwC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Rami Elghandour, David Lubner, and Kristin Myers elected as Class III directors with 42.8M, 38.9M, and 49.3M votes for, respectively.","Advisory vote on executive compensation approved: 39.9M for, 9.5M against, 5.9K abstain (approx. 81% support).","Ratification of PricewaterhouseCoopers as auditor for FY2025 passed with 52.7M for, 252K against, 4.8K abstain.","Approximately 96.15% of outstanding shares represented at the May 28, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159557,"accession_number":"0001193125-25-119506","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcellx reports 97% ORR and 68% CR/sCR in Phase 2 anito-cel study for RRMM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 iMMagine-1 (117 patients) showed 97% ORR and 68% CR/sCR at median 12.6 months follow-up.","No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) or immune-mediated enterocolitis.","12-month PFS rate 78.8%, OS rate 95.2%; median PFS and OS not reached.","Data to be presented at EHA2025 on June 14; commercial launch with Kite planned for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159556,"accession_number":"0001193125-25-116023","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcellx Q1 net loss $62.3M; cash $565M; iMMagine-3 adds MRD endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $62.3M vs $7.2M in Q1 2024; collaboration revenue down to $8.1M from $39.3M.","Cash and equivalents $565.2M; funding expected into 2028.","iMMagine-1 data (117 patients) accepted for oral presentation at EHA June 14, 2025.","iMMagine-3 study updated to include MRD negativity as dual primary endpoint alongside PFS.","Appointed Andrew Galligan and Kristin Myers to Board; anito-cel launch planned for 2026."],"consensus_eps_estimate":-0.7726,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":8129000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177927,"accession_number":"0001193125-25-058978","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Arcellx appoints Andrew Galligan and Kristin Myers to board; Derek Yoon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Derek Yoon resigned from the board effective March 18, 2025; no disagreements.","Board size expanded from 7 to 8; Galligan and Myers appointed as Class I and III directors.","Galligan brings financial leadership (ex-CFO of Nevro, Ooma); Myers adds payer/provider expertise (COO of Blue Cross Blue Shield Assn.).","New directors receive $50k annual retainer, $850k initial option grant (3-yr vest), and $425k annual option grant.","Company highlights anito-cel progress and expects commercial launch in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177926,"accession_number":"0001193125-25-039316","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcellx FY2024 net loss $107.3M; anito-cel Phase 2 shows 97% ORR, 62% CR/sCR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $625.7M; runway into 2027.","Collaboration revenue $107.9M in FY2024 vs $110.3M in FY2023.","Net loss $107.3M for FY2024 vs $70.7M prior year; R&D spend $157.1M.","Anito-cel pivotal iMMagine-1 data: 97% ORR, 62% CR/sCR (n=86), no delayed neurotoxicities.","Commercial launch of anito-cel in RRMM planned for 2026; iMMagine-1 update mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":107936000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194640,"accession_number":"0001193125-24-275844","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcellx reports positive Phase 2 anito-cel data for relapsed/refractory multiple myeloma at ASH 2024","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Hosted investor webcast at ASH highlighting new positive data from Phase 2 pivotal iMMagine-1 study of anito-cel.","Study evaluates anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma.","Filing notes data as positive but does not disclose specific efficacy or safety numbers.","Corporate presentation attached as Exhibit 99.1 provides further details not included in this summary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194639,"accession_number":"0001193125-24-272814","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcellx iMMagine-1 study: 97% ORR, 62% CR/sCR, no delayed neurotoxicity in RRMM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 pivotal iMMagine-1: 86 patients evaluable; ORR 97% (83/86), CR/sCR 62% (53/86) at median 9.5-month follow-up.","No delayed neurotoxicities (Parkinsonism, cranial nerve palsies, Guillain-Barré) in >150 dosed patients across Phase 1 and iMMagine-1.","Phase 1 study shows 30.2-month median PFS at 38.1 months follow-up; median OS not reached.","MRD negativity achieved in 93.1% (54/58) evaluable at ≥10⁻⁵ sensitivity.","Safety: 86% had Grade ≤1 CRS; 91% had no ICANS; most common Grade ≥3 TEAE was neutropenia (54%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194638,"accession_number":"0001193125-24-253174","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcellx Q3 net loss narrows; anito-cel hits 95% ORR in pivotal study with no neurotoxicity","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net loss $25.9M ($39.3M YoY); collaboration revenue $26M from Kite expansion.","Phase 2 iMMagine-1 (n=58): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity.","Phase 1 anito-cel: 30.2-month mPFS, median OS not reached at 38.1 months; 100% ORR.","No delayed neurotoxicity (parkinsonism, cranial nerve palsies) in >140 patients across trials.","Cash $676.7M funds into 2027; first patients dosed in iMMagine-3 with Kite manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":92670000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194637,"accession_number":"0001193125-24-251014","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arcellx updates anito-cel data: Phase 1 median PFS 30.2 months; iMMagine-1 95% ORR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 study (38 patients): 100% ORR, 79% CR/sCR, median PFS 30.2 months at 38.1 months median follow-up; median OS not reached.","iMMagine-1 (58 patients): 95% ORR, 62% CR/sCR, median follow-up 10.3 months; 92% MRD negativity at 10^-5.","No delayed neurotoxicities (no parkinsonism, no cranial nerve palsies, no Guillain-Barré) observed across >140 patients dosed.","First patient dosed in iMMagine-3 study (earlier lines); manufactured by Kite with turnaround time in line with Kite's commercial products.","Data to be presented at ASH Annual Meeting Dec 7-10, 2024; company webcast Dec 9 at 8:30 p.m. PT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210943,"accession_number":"0001193125-24-197017","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcellx Q2 net loss $27.2M; earns $68M milestone from Kite; IND cleared for myasthenia gravis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Earned $68M milestone from Kite for iMMagine-1 enrollment in multiple myeloma.","Cash, equivalents, and marketable securities $646.8M as of June 30, 2024; funds operations into 2027.","Collaboration revenue $27.4M (up from $14.3M YoY); net loss $27.2M vs $23.9M YoY.","FDA cleared anito-cel IND for myasthenia gravis, a chronic autoimmune disease; wholly owned by Arcellx.","Kite initiated global Phase 3 iMMagine-3; abstract submitted for ASH Annual Meeting by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":66640000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229400,"accession_number":"0001193125-24-148245","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Arcellx shareholders re-elect three directors; say-on-pay approved with 56% support","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jill Carroll, Kavita Patel, Olivia Ware re-elected as Class II directors through 2027.","Say-on-pay approved with 25,553,954 for, 19,766,928 against, 42,869 abstain, 3,807,689 broker non-votes.","Future say-on-pay votes set for every one year; 45,293,520 votes for 1-year frequency.","Ratification of PricewaterhouseCoopers as independent auditor for FY2024 approved with 49,117,994 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229399,"accession_number":"0001193125-24-135267","cik":1786205,"company_name":"Arcellx, Inc.","ticker":"ACLX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arcellx Q1 net loss narrows to $7.2M; collaboration revenue rises to $39.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities of $691.0M as of March 31, 2024; funds operations into 2027.","Collaboration revenue $39.3M, up $21.4M YoY, driven by Kite Pharma agreement amendments.","Net loss of $7.2M vs $27.3M in Q1 2023, an improvement of $20.1M.","R&D expenses $32.3M (down $0.6M YoY); G&A expenses $22.7M (up $7.3M YoY) on higher personnel costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":39256000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6729270000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}